Clinical trial
Almonertinib Alone Versus Almonertinib Plus Chemotherapy as First-Line Treatment in Locally Advanced Or Metastatic NSCLC Patients With Concomitant EGFR and Tumor Suppressor Gene Mutation: A Multicenter, Open-Label, Randomized, Controlled Phase III Study (ACROSS2)
NCT04500717 is registered in ClinicalTrials.gov with Cancer Institute and Hospital, Chinese Academy of Medical Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Almonertinib Alone Versus Almonertinib Plus Chemotherapy as First-Line Treatment in Locally Advanced Or Metastatic NSCLC Patients With Concomitant EGFR and Tumor Suppressor Gene Mutation: A Multicenter, Open-Label, Randomized, Controlled Phase III Study (ACROSS2)
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- October 31, 2020
- Completion date
- October 31, 2023
- Enrollment
- 460 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
non small cell lung cancer